에이비프로바이오
195990KOSDAQ특수 목적용 기계 제조업43.5 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
AB ProBio operates three core business segments: a machine tool division specializing in small machining centers (UT and MAX series), a biopharmaceutical development division that acquired rights to develop dual-antibody drugs targeting HER2 and VEGF from Abpro Corporation, and a semiconductor equipment division expanded through the acquisition of ANAH in 2023. The company produces high-performance machining centers tailored for IT and electronics manufacturing, while advancing biopharmaceutical R&D in Asia, CIS countries, and the Middle East.
Number of Employees
43people
Average Salary
0.1M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
Well below industry avg
3.0x industry avg (risky)
Avg ▲12.8% (2-year basis)
Avg ▼3.4% (2-year basis)
Avg ROE -31.2% (declining, 3yr)
Detailed News Sentiment
- Negative새 최대주주 맞은 서울전자통신, 자회사 매각 계약금 반환에 반대매매.....
서울전자통신의 최대주주 변경과 계약금 반환 소송 결과로 재무 부담 증가 및 반대매매 리스크 상승으로 인해 에이비프로바이오에 부정적 영향 예상.
- Positive에이비프로바이오, 2대 1 주식병합 결정
에이비프로바이오의 주식병합 결정으로 주가 안정화와 기업 가치 제고 기대.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -35.13% (strong drop)
Volume dry-up
Detailed Disclosure
- Neutral[기재정정]의결권대리행사권유참고서류2026-05-27
- Neutral[기재정정]주주총회소집공고2026-05-27
- Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-05-27
- Neutral[기재정정]주식병합결정2026-05-27
- Neutral주주총회소집공고2026-05-20
